参考文献/References:
[1] Moran AEForouzanfar MH,Roth GA,et al.The global burden of ischemic heart disease in 1990 and 2010:the Global Burden of Disease 2010 study[J].Circulation,2014,129(14):1493-1501.
[2] Go AS,Mozaffarian D,Roger VL,et al.Executive summary:heart disease and stroke statistics--2014 update:a report from the American Heart Association[J].Circulation,2014,129(3):399-410.
[3] 朱永翔李烽张耀庭等沙库巴曲缬沙坦在射血分数降低性心力衰竭患者治疗中的研究进展[J]心血管病学进展,2019,(9):1249-1252.
[4] Meyer MSchillinger W,Pieske B,et al.Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy[J].Circulation,1995,92(4):778-784.
[5] Kawase Y,Ly HQ,Prunier F,et al.Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure[J].J Am Coll Cardiol,2008,51(11):1112-1119.
[6] Brodde OE,Michel MC,Zerkowski HR.Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure[J].Cardiovasc Res,1995,30(4):570-584.
[7] Tang T,Gao MH,Roth DM,et al.Adenylyl cyclase type Ⅵ corrects cardiac sarcoplasmic reticulum calcium uptake defects in cardiomyopathy[J].Am J Physiol Heart Circ Physiol,2004,287(5):H1906-1912.
[8] Roth DM,Bayat H,Drumm JD,et al.Adenylyl cyclase increases survival in cardiomyopathy[J].Circulation,2002,105(16):1989-1994.
[9] Gao MH,Tang T,Guo T,et al.Adenylyl cyclase type Ⅵ gene transfer reduces phospholamban expression in cardiac myocytes via activating transcription factor 3[J].J Biol Chem,2004,279(37):38797-38802.
[10] Gao MH,Bayat H,Roth DM,et al.Controlled expression of cardiac-directed adenylylcyclase type VI provides increased contractile function[J].Cardiovasc Res,2002,56(2):197-204.
[11] Sundararaman S,Miller TJ,Pastore JM,et al.Plasmid-based transient human stromal cell-derived factor-1 gene transfer improves cardiac function in chronic heart failure[J].Gene Ther,2011,18(9):867-873.
[12] Yamaguchi J,Kusano KF,Masuo O,et al.Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization[J].Circulation,2003,107(9):1322-1328.
[13] Jaski BE,Jessup ML,Mancini DM,et al.Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial),a first-in-human phase 1/2 clinical trial[J].J Card Fail,2009,15(3):171-181.
[14] Jessup M,Greenberg B,Mancini D,et al.Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID):a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure[J].Circulation,2011,124(3):304-313.
[15] Zsebo K,Yaroshinsky A,Rudy JJ,et al.Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure:analysis of recurrent cardiovascular events and mortality[J].Circ Res,2014,114(1):101-108.
[16] Greenberg B,Yaroshinsky A,Zsebo KM,et al.Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure:the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b)[J].JACC Heart Fail,2014,2(1):84-92.
[17] Greenberg B,Butler J,Felker GM,et al.Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2):a randomised,multinational,double-blind,placebo-controlled,phase 2b trial[J].Lancet,2016,387(10024):1178-1186.
[18] Mingozzi F,Anguela XM,Pavani G,et al.Overcoming preexisting humoral immunity to AAV using capsid decoys[J].Sci Transl Med,2013,5(194):194ra192.
[19] Hammond HK,Penny WF,Traverse JH,et al.Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure:a randomized clinical trial[J].JAMA Cardiol,2016,1(2):163-171.
[20] Penny WF,Henry TD,Watkins MW,et al.Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction:The FLOURISH Clinical Trial[J].Am Heart J,2018,201:111-116.
[21] Penn MS,Mendelsohn FO,Schaer GL,et al.An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure[J].Circ Res,2013,112(5):816-825.
[22] Chung ES,Miller L,Patel AN,et al.Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients:the STOP-HF randomized Phase Ⅱ trial[J].Eur Heart J,2015,36(33):2228-2238.
[23] Watanabe S,Ishikawa K,Fish K,et al.Protein phosphatase inhibitor-1 gene therapy in a swine model of nonischemic heart failure[J].J Am Coll Cardiol,2017,70(14):1744-1756.
[24] Amoasii L,Hildyard JCW,Li H,et al.Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy[J].Science,2018,362(6410):86-91.
[25] Gabisonia K,Prosdocimo G,Aquaro GD,et al.MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs[J].Nature,2019,569(7756):418-422.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(6):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(6):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(6):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(6):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(6):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(6):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(6):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]